Immunocore (NASDAQ:IMCR) Rating Reiterated by Leerink Partnrs

Immunocore (NASDAQ:IMCR)‘s stock had its “outperform” rating restated by analysts at Leerink Partnrs in a report released on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for Immunocore’s Q1 2024 earnings at ($0.49) EPS, Q2 2024 earnings at ($0.41) EPS, Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.58) EPS and FY2025 earnings at ($2.14) EPS.

Several other equities research analysts have also recently issued reports on IMCR. Oppenheimer restated an “outperform” rating and issued a $87.00 target price (up previously from $85.00) on shares of Immunocore in a report on Thursday, February 29th. Guggenheim restated a “buy” rating and issued a $92.00 target price on shares of Immunocore in a report on Tuesday, April 23rd. Mizuho raised their target price on shares of Immunocore from $86.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Canaccord Genuity Group raised their target price on shares of Immunocore from $60.00 to $63.00 and gave the stock a “hold” rating in a report on Thursday, February 29th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $80.92.

Immunocore Price Performance

Shares of IMCR opened at $59.05 on Monday. The company has a market capitalization of $2.94 billion, a P/E ratio of -50.90 and a beta of 0.92. The company has a quick ratio of 3.77, a current ratio of 3.80 and a debt-to-equity ratio of 0.13. The firm has a 50 day moving average of $61.68 and a 200 day moving average of $60.94. Immunocore has a twelve month low of $42.21 and a twelve month high of $76.98.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.12). Immunocore had a negative net margin of 22.48% and a negative return on equity of 15.78%. The firm had revenue of $70.16 million for the quarter, compared to the consensus estimate of $53.25 million. During the same period last year, the business earned ($0.63) EPS. Immunocore’s revenue was up 22.4% on a year-over-year basis. As a group, equities research analysts anticipate that Immunocore will post -1.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IMCR. Bellevue Group AG lifted its stake in shares of Immunocore by 4,817.1% during the 4th quarter. Bellevue Group AG now owns 976,054 shares of the company’s stock valued at $66,684,000 after buying an additional 956,204 shares in the last quarter. Braidwell LP increased its holdings in Immunocore by 93.8% in the 3rd quarter. Braidwell LP now owns 906,973 shares of the company’s stock valued at $47,072,000 after acquiring an additional 438,946 shares during the last quarter. Wellington Management Group LLP increased its holdings in Immunocore by 10.2% in the 4th quarter. Wellington Management Group LLP now owns 4,312,611 shares of the company’s stock valued at $294,638,000 after acquiring an additional 399,201 shares during the last quarter. First Turn Management LLC bought a new stake in Immunocore in the 4th quarter valued at $23,439,000. Finally, Polar Capital Holdings Plc increased its holdings in Immunocore by 490.5% in the 3rd quarter. Polar Capital Holdings Plc now owns 250,000 shares of the company’s stock valued at $12,975,000 after acquiring an additional 207,664 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.